
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. is anticipated to experience significant revenue growth driven by its Signatera molecular residual disease testing, with recent quarters showing a notable increase of 21,500 volumes quarter-over-quarter, translating to a robust 54% year-over-year growth. The company has outlined plans to expand reimbursement coverage for Signatera across various cancer types, which is expected to enhance average selling prices, gross margins, and operating cash flow. Additionally, Natera's recent financial performance included an approximately $80 million revenue beat in the third quarter and an upward revision of its 2025 revenue guidance by $160 million, reflecting strong operational momentum.
Bears say
Natera anticipates continued margin erosion due to reductions in in-network pricing as it expands its total addressable market to incorporate more average-risk patients. The company faces significant risks from potential negative developments such as regulatory issues, reimbursement challenges, and delays in product launches, which could adversely impact its stock performance. Additionally, competition from firms like Guardant Health, which may struggle with reimbursement and adoption in emerging markets, presents further pressure on Natera's growth prospects in the diagnostic space.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares